エピソード

  • UnitedHealth Q3 2026 Earnings Analysis

    UnitedHealth Q3 2026 Earnings Analysis
    2026/10/15
    More earnings analysis: https://betafinch.com
    Groups: HEALTHCARE (https://betafinch.com/groups/HEALTHCARE)
    ──────────
    WELCOME TO BETA FINCH

    ALEX: Welcome to Beta Finch, your AI-powered earnings breakdown, where we take the numbers and the jargon from corporate earnings calls and turn them into something you can actually digest. I'm Alex.

    JORDAN: And I'm Jordan. Today we're diving into UnitedHealth Group — ticker UNH — and their third quarter 2026 results, reported this week.

    ALEX: Before we get into it, quick disclaimer: this podcast is AI-generated content for educational and entertainment purposes only. Nothing we discuss should be considered investment advice. Always do your own research and consult a qualified financial advisor before making any investment decisions.

    JORDAN: Good to have that out front. So Alex, this was actually a pretty encouraging quarter for UnitedHealth after a rough stretch.

    ALEX: It really was. Let's start with the headline numbers. Revenue came in at $113 billion for the quarter. Adjusted earnings per share was $4.69 — compare that to just $2.92 a year ago. That's a massive jump.

    JORDAN: And the metric everyone watches in this industry, the medical care ratio — basically what percentage of premium revenue goes out the door paying for medical claims — improved to 88.4%, down from 89.9% last year. Lower is better here, it means they're managing costs more effectively relative to what they're bringing in.

    ALEX: Right, and on the back of that they raised full-year guidance to at least $20.50 in adjusted EPS. CFO Wayne DeVeydt called that a "solid run rate to grow from," and interestingly, management said they think Wall Street's 2027 estimates might actually be too conservative.

    JORDAN: That's a confident thing to say out loud on an earnings call. They're essentially telling analysts, "you might be underestimating us."

    ALEX: Let's talk segments for a second. UnitedHealthcare, the insurance arm, served 48.3 million people. Optum, their services arm, posted $66.9 billion in revenue — though Optum Health specifically saw a 10% revenue decline, which sounds alarming at first.

    JORDAN: It does, but context matters. That's really a reflection of them pulling back from certain full-risk arrangements and refocusing on more disciplined, value-based care contracts rather than just chasing volume. Quality over quantity, essentially.

    ALEX: Now here's the thing that jumped out at me — commercial medical trend, meaning cost growth in their employer-sponsored insurance business, is running above 11%. That's way above historical norms.

    JORDAN: And they were pretty pointed about why. Two big drivers: high-cost specialty drugs, which is an industry-wide story at this point, and something more unique to UnitedHealth's commentary — arbitration awards tied to the No Surprises Act.

    ALEX: Explain that one, because it's a little wonky.

    JORDAN: Sure. The No Surprises Act was designed to protect patients from surprise out-of-network bills. But there's a dispute resolution process built into it, and UnitedHealth is saying certain provider groups are gaming that process — arbitration awards in some regions are approaching 6% of total medical spend. Management was blunt, calling it "abuse" of the system, and said it's translating to billions in excess costs.

    ALEX: So this isn't just "healthcare costs are high," it's "there's a specific regulatory mechanism being exploited."

    JORDAN: Exactly, and they're actively lobbying regulators on it. Worth watching into 2027.

    ALEX: Let's shift to the strategic story, because this is where it gets interesting. CEO Steve Hemsley leaned hard into AI throughout the call. They've rolled out AI-enabled chart summarization to over 40% of employed clinicians, cutting chart review time by a third. AI-assisted appeals processing cut cycle times by 26%.

    JORDAN: And the big one for anyone who's ever dealt with insurance red tape — they're on track to cut prior authorization volumes by 30%

    This episode includes AI-generated content.
    続きを読む 一部表示
    7 分
  • Medtronic Q1 2027 Earnings Analysis

    Medtronic Q1 2027 Earnings Analysis
    2026/09/01
    More earnings analysis: https://betafinch.com
    Groups: HEALTHCARE (https://betafinch.com/groups/HEALTHCARE)
    ──────────
    WELCOME TO BETA FINCH — MEDTRONIC Q1 FY2027

    ALEX: Welcome to Beta Finch, your AI-powered earnings breakdown. I'm Alex, joined as always by Jordan, and today we're digging into Medtronic's fiscal 2027 first quarter — and it's a big one.

    JORDAN: Yeah, a lot to unpack here. Big beats, a couple of surprise M&A announcements, and a robotics story that's getting more interesting by the day.

    ALEX: Before we jump in, quick note — this podcast is AI-generated content for educational and entertainment purposes only. Nothing we discuss should be considered investment advice. Always do your own research and consult a qualified financial advisor before making any investment decisions.

    JORDAN: With that out of the way, let's get into the numbers, because they were strong.

    ALEX: $9.8 billion in revenue, up 13.7% organically, adjusted EPS of $1.45 — both well ahead of what analysts were expecting. Now, a chunk of that growth came from an accounting quirk: fiscal 2027 is a 53-week year, and that extra week added about 670 basis points to growth this quarter.

    JORDAN: Right, but even stripping that out, CFO Thierry Piéton said it was their strongest quarterly performance in nearly eight years, excluding COVID comparisons. So this wasn't just a calendar trick — the underlying business is actually accelerating.

    ALEX: And it was broad-based. CEO Geoff Martha kept hammering that point — it's not one hot product carrying the quarter, it's basically every major business line pulling its weight.

    JORDAN: The headline story, though, is Cardiac Ablation Solutions — CAS. That business grew 88% worldwide, 139% in the U.S. They crossed $2 billion in trailing twelve-month revenue, ahead of schedule. Their Sphere-9 catheter picked up nine points of U.S. market share this quarter alone.

    ALEX: Nine points in one quarter is wild for medtech.

    JORDAN: It really is. And they're guiding CAS to grow at 2.5 times the broader electrophysiology market for the full year — even upgraded that to more than 3x for Q2. The U.S. installed base for their Affera system grew 35% sequentially, on top of 40% the quarter before.

    ALEX: Which tells you they're nowhere near saturated. Management said 75% of that installed base is still concentrated in high-volume hospital centers, so there's a long runway into smaller accounts.

    JORDAN: Beyond CAS, Cardiac Rhythm Management grew 15%, Cranial & Spinal Technologies grew 13%, and Surgical — their biggest unit at over $6 billion a year — grew 9%. Pelvic health jumped 15%, largely thanks to Altaviva, where procedures doubled sequentially.

    ALEX: Now let's talk strategy, because Medtronic made two acquisition-adjacent announcements the same morning as earnings. First, a $700 million strategic investment and distribution deal with Cornerstone Robotics for their Sentire surgical robot, outside the U.S.

    JORDAN: This one got some pointed questions on the call. One analyst basically asked, "Does this mean you've lost confidence in Hugo, your own robot?" And Martha pushed back hard — said it's the opposite. Hugo's on track to hit 50,000 procedures by year-end, growing at twice the market rate. Cornerstone is about extending reach into international markets where Hugo isn't the right fit, not replacing it.

    ALEX: Basically building a multi-platform robotics portfolio instead of betting everything on one system.

    JORDAN: Exactly — and Thierry noted the financial impact this year is minimal, mostly just some foregone interest on that investment, but they expect real revenue and margin lift starting in fiscal 2028.

    ALEX: The second deal was Pi-Cardia, in structural heart — first FDA-cleared technology for leaflet modification in TAVR procedures for patients at risk of coronary obstruction. That's part of a broader doubling-down in structural heart, alongside their earlier investment in Anteris.

    JORDAN: On guidance, they ra

    This episode includes AI-generated content.
    続きを読む 一部表示
    7 分
  • Stryker Q2 2026 Earnings Analysis

    Stryker Q2 2026 Earnings Analysis
    2026/07/31
    More earnings analysis: https://betafinch.com
    Groups: HEALTHCARE (https://betafinch.com/groups/HEALTHCARE)
    ──────────
    ALEX: Welcome to Beta Finch, your AI-powered earnings breakdown! Today we're digging into Stryker's Q2 2026 results — and this is a good one, because it's really a comeback story.

    But first — this podcast is AI-generated content for educational and entertainment purposes only. Nothing we discuss should be considered investment advice. Always do your own research and consult a qualified financial advisor before making any investment decisions.

    JORDAN: Okay, so context matters a lot here. Stryker got hit by a cybersecurity incident that knocked out manufacturing for about a month in Q1. So Q2 is really the "how fast can they recover" quarter.

    ALEX: And the answer is — pretty fast. Organic sales growth of 9%, adjusted EPS of $3.69, up almost 18% year over year. For a $25 billion company that had plants offline for weeks, that's a strong number.

    JORDAN: Right, CEO Kevin Lobo actually said it himself on the call — growing around 9% "given that we were knocked out for almost an entire month" is a pretty good outcome. And you saw strength pretty much everywhere: MedSurg and Neurotechnology up over 9%, Orthopedics up 8.6%. U.S. trauma and extremities grew over 12%, medical devices — Sage, Emergency Care — grew north of 13%.

    ALEX: The one soft spot was peripheral vascular, down almost 7% in the U.S. There was a supply disruption at one of their Inari manufacturing plants that caused a real backorder problem. They actually had to ration product to their best customers.

    JORDAN: Which is a rough thing to say out loud on an earnings call, but at least it's honest. Management expects that backorder to work itself down to manageable levels by the end of Q3, and they're still bullish long-term on that business — especially with the AVS acquisition that just closed, which adds an IVL, intravascular lithotripsy, product to the portfolio.

    ALEX: Let's talk strategy for a second, because there were some real headline moments here. Mako, their robotics platform, just turned 20 years old, and they had their best-ever second quarter for Mako installations, both in the U.S. and internationally. Over 2.5 million procedures done globally now, systems in 47 countries.

    JORDAN: And the bigger story is the full commercial launch of Mako RPS — that's their handheld robotics system. It's aimed at surgeons who aren't ready to commit to a full Mako cart, especially in ambulatory surgery centers doing total knees. Lobo said the haptic feedback is what's really wowing surgeons — that you can get that kind of precision in a handheld device.

    ALEX: They're also rolling out Triathlon Gold, a new insert for their knee system, a new total ankle replacement called Encompass, and a trauma plating system called Pangaea that's launching in Europe. So despite the manufacturing hit, the product pipeline didn't really slow down.

    JORDAN: Now, the money question everyone on the call kept circling back to — capital equipment. Stryker's sitting on an elevated order backlog because demand outpaced their ability to produce during the recovery. Beds, in particular — their ProCuity hospital bed business — has huge order volume they just haven't been able to fill yet.

    ALEX: And management's plan is straightforward: add manufacturing shifts and grind through the backlog in the second half of the year. Lobo was pretty confident about this, saying these aren't new products, this is stuff they know how to make — it's purely an execution and capacity question, not a demand question.

    JORDAN: That came up a lot in the Q&A, actually — analysts pushing hard on whether Stryker can really hit an implied 11% organic growth rate in the back half to reach their guidance midpoint. Lobo's response was basically, "we raised the low end of our guidance from 8% to 8.3%, that alone should tell you how confident we are."

    ALEX: On guidance — they narrowed the full-year range. O

    This episode includes AI-generated content.
    続きを読む 一部表示
    7 分
  • Boston Scientific Q2 2026 Earnings Analysis

    Boston Scientific Q2 2026 Earnings Analysis
    2026/07/29
    More earnings analysis: https://betafinch.com
    Groups: HEALTHCARE (https://betafinch.com/groups/HEALTHCARE)
    ──────────
    ALEX: Welcome to Beta Finch, your AI-powered earnings breakdown. Today we're diving into Boston Scientific's second quarter 2026 results — and Jordan, this one's got some real drama in it.

    JORDAN: It really does. Before we jump in, quick disclaimer for everyone listening: this podcast is AI-generated content for educational and entertainment purposes only. Nothing we discuss should be considered investment advice. Always do your own research and consult a qualified financial advisor before making any investment decisions.

    ALEX: Right, so let's set the scene. Boston Scientific actually beat expectations in Q2 — organic sales grew 7%, ahead of their 5-7% guide, and adjusted EPS came in at 86 cents, up 15% year-over-year and above the high end of guidance.

    JORDAN: On paper, that sounds like a great quarter. But here's the twist — right after touting the beat, management turned around and cut full-year guidance. Full-year organic revenue guidance moved down to 5-6%, and full-year EPS guidance came in at $3.28 to $3.32.

    ALEX: And the culprit? Two of their hottest businesses over the last couple years — WATCHMAN and electrophysiology, or EP.

    JORDAN: Let's start with WATCHMAN, the left atrial appendage closure device. This is a fascinating case of clinical evidence essentially colliding with commercial momentum. New studies — OCEAN, CHAMPION-AF — have been published over the past several months, and they're changing how doctors think about referring patients for the procedure.

    ALEX: CEO Mike Mahoney was pretty candid about it. He said the U.S. market has "slowed sharply and unexpectedly." Standalone WATCHMAN procedures — meaning not done alongside another heart procedure — are actually declining in the low teens percentage-wise.

    JORDAN: The one bright spot is "concomitant" procedures — done at the same time as another cardiac procedure — which grew over 60%. But even that's expected to slow in the second half because of tougher comparisons.

    ALEX: So full-year WATCHMAN growth guidance is now flat to low single digits, with the second half actually expected to decline mid-to-high single digits. That's a big swing from where this business has been.

    JORDAN: Then there's EP, the electrophysiology business built around their FARAPULSE technology — that's the pulsed field ablation, or PFA, platform for treating atrial fibrillation. Management admitted they simply underestimated competitive pressure in the U.S.

    ALEX: Which is almost ironic, because Boston Scientific basically created this PFA market boom. Mahoney noted PFA now makes up something like 80% of the U.S. AFib ablation market — a shift that happened faster than anyone expected, and that success invited competitors in quicker than the company modeled.

    JORDAN: Meanwhile, international EP growth is still humming along around 20%. It's really a U.S.-specific share story, not a "the technology doesn't work" story.

    ALEX: Here's something I found reassuring, though. Management pointed out that roughly 75% of Boston Scientific's revenue — everything outside WATCHMAN and EP — is still expected to grow about 6% in the second half, which is right in line with their historical trend.

    JORDAN: Right, and there were genuinely strong pockets. Neuromodulation grew 12%. Interventional cardiology grew 15%. Interventional oncology grew 12%. This isn't a company falling apart — it's two specific franchises hitting an air pocket.

    ALEX: Let's talk strategy, because they also announced a restructuring program targeting about $500 million in run-rate savings by the end of 2029, with more than half of that realized by exiting 2027.

    JORDAN: That's a real signal — they're bracing for a tougher stretch and want to fund future growth catalysts without blowing up margins. CFO Jon Monson said savings will show up first in SG&A, then in cost of goods sold over time.

    ALEX: And on th

    This episode includes AI-generated content.
    続きを読む 一部表示
    7 分
  • Thermo Fisher Scientific Q2 2026 Earnings Analysis

    Thermo Fisher Scientific Q2 2026 Earnings Analysis
    2026/07/23
    More earnings analysis: https://betafinch.com
    Groups: HEALTHCARE (https://betafinch.com/groups/HEALTHCARE)
    ──────────
    **Beta Finch: Thermo Fisher Scientific (TMO) Q2 2026 Earnings Breakdown**

    ALEX: Welcome to Beta Finch, your AI-powered earnings breakdown. Today we're digging into Thermo Fisher Scientific's second quarter 2026 results, and Jordan, this is a genuinely strong print to sink our teeth into.

    JORDAN: Before we get into it, quick disclaimer for everyone listening. This podcast is AI-generated content for educational and entertainment purposes only. Nothing we discuss should be considered investment advice. Always do your own research and consult a qualified financial advisor before making any investment decisions.

    ALEX: Right, with that out of the way, let's talk numbers. Thermo Fisher posted revenue of $11.99 billion, up 10% year-over-year. Adjusted operating income jumped 15% to $2.73 billion, and adjusted EPS grew 13% to $6.03 a share.

    JORDAN: And what jumps out to me is that this wasn't a "beat on cost-cutting" quarter — this was a genuine top-line story. Organic revenue growth came in at 5%, which management explicitly said was about 2 points ahead of their own prior guidance. Margins expanded too — adjusted operating margin hit 22.8%, up 90 basis points. That's the kind of quarter where basically everything worked at once.

    ALEX: Let's break down where that growth came from. All four end markets grew mid-single-digits or better. Pharma and biotech — their biggest bucket at roughly 60% of revenue — grew mid-single digits, led by bioproduction and clinical research. Industrial and applied also grew mid-single digits, diagnostics and healthcare grew mid-single digits, and even academic and government, which has been the soft spot for a while, returned to growth, albeit low single digits.

    JORDAN: That academic and government comeback is worth sitting with for a second. CEO Marc Casper was careful not to declare victory there — he said they want to see it "more broad-based" before calling it a real trend. But the U.S. turned slightly positive, Europe was actually quite strong, and interestingly China stayed muted in that segment specifically. So it's a cautious green shoot, not a full recovery.

    ALEX: Speaking of China — it's about 7.5% of total revenue and grew low single digits, which is its first return to growth in a while. Casper credited that to pharma/biotech and industrial and applied demand, while academic spending there remains flat. He was clear it's not yet accretive to overall company growth, but the trajectory is improving.

    JORDAN: Now let's talk capital moves, because there's a lot going on here. Thermo Fisher closed the Clario acquisition in late March — that's digital clinical trial endpoint data — and it had a strong first full quarter of ownership. They also closed the filtration and separation business, formerly part of 3M/Solventum, which is showing strong demand and they're actually adding capacity.

    ALEX: And on the flip side, they're divesting their microbiology business, expected to close in Q3. That business did about $645 million in revenue in 2025. They used the anticipated proceeds to fund a $1 billion share buyback in the quarter — so essentially pre-funding the repurchase ahead of the deal closing.

    JORDAN: That divestiture does create some near-term drag, worth flagging for anyone modeling this out — management said it reduces 2026 revenue by about $200 million net of retained channel sales, and dings adjusted EPS by about $0.05 this year, growing to roughly $0.15 dilutive in the first full year after close.

    ALEX: Which makes the guidance raise even more impressive, because it absorbs that headwind and still goes up. New revenue guidance is $47.4 to $48.1 billion, representing 6-8% reported growth. Organic growth guidance moved to "about 4%" for the full year — they kept the 3-4% range but said they now expect to land at the top of it. Adjusted EPS guidance rose to $24.93 to $2

    This episode includes AI-generated content.
    続きを読む 一部表示
    8 分
  • Intuitive Surgical Q2 2026 Earnings Analysis

    Intuitive Surgical Q2 2026 Earnings Analysis
    2026/07/22
    More earnings analysis: https://betafinch.com
    Groups: HEALTHCARE (https://betafinch.com/groups/HEALTHCARE)
    ──────────
    ALEX: Welcome to Beta Finch, your AI-powered earnings breakdown! Today we're diving into Intuitive Surgical's second quarter 2026 results. Before we get going, I do need to say — this podcast is AI-generated content for educational and entertainment purposes only. Nothing we discuss should be considered investment advice. Always do your own research and consult a qualified financial advisor before making any investment decisions.

    JORDAN: And with that out of the way, Alex, this was actually a pretty strong quarter for Intuitive on paper.

    ALEX: It was. Revenue up 19% to $2.89 billion, non-GAAP EPS up 28% to $2.80 a share, operating margin at 42%. Total procedures grew 16%, with da Vinci procedures up 15% and Ion — their lung biopsy platform — up a huge 36%.

    JORDAN: There's a wrinkle in that gross margin number though. It came in at 70%, but $36 million of that was a one-time tariff refund benefit. Strip that out and you're looking at 68.7%, which is still solid, but worth noting when you're comparing quarters.

    ALEX: Right, and they actually raised full-year gross margin guidance because of that — now 68% to 69%, up from 67.5% to 68.5%. But here's the part that got analysts' attention: U.S. da Vinci procedure growth moderated to 12%, down from 14% in Q1.

    JORDAN: Yeah, and CFO Jamie Samath was pretty direct about why. They're seeing signs that patients are deferring elective procedures, and they specifically flagged the expiration of ACA enhanced premium subsidies as a factor. Basically, when people's insurance costs go up or coverage gets murkier, they push off surgeries that can wait.

    ALEX: The CEO, Dave Rosa, made a point of saying the underlying disease burden hasn't changed — people aren't getting healthier, they're just delaying care. Which, if you're an investor, is either reassuring or a "wait and see," depending on how you read it.

    JORDAN: There's also the GLP-1 story continuing to play out — bariatric procedures in the U.S. declined high-single-digits this quarter as more patients manage weight through drugs like Ozempic instead of surgery.

    ALEX: Let's talk strategy, because there was a lot packed into this call. The big one: the Extended Use Program. Starting in early 2027, Intuitive plans to increase the number of uses allowed on a subset of their EndoWrist instruments, specifically targeting lower-cost, high-volume benign procedures.

    JORDAN: This is a classic Intuitive move — they did something similar back in 2020. The idea is: lower the cost per procedure for hospitals, which drives more adoption, which drives more scale. An analyst on the call, Travis Steed, tried to get them to size the financial impact — he was fishing for whether this repeats the roughly 7-point hit to instrument revenue per procedure they saw last time.

    ALEX: And management wouldn't bite. Jamie Samath said flat out they're not ready to quantify it and will give more detail next quarter. So that's a real overhang to watch heading into 2027 guidance.

    JORDAN: The other big theme was geographic. China remains genuinely tough — increased domestic robotic competition, pricing pressure, and a new centralized tender process the government is rolling out. Dave Rosa was careful to say it's not quite the same as the volume-based pricing programs we've seen hit other device makers, but it's clearly something to watch.

    ALEX: Japan, on the other hand, looked more encouraging. New reimbursement policies kicked in June 1st, and they already saw system placements jump — 25 systems in Japan this quarter versus 15 a year ago.

    JORDAN: And then there's da Vinci 5, which is really the growth engine right now. They placed 468 total da Vinci systems, 246 of those were da Vinci 5, including 114 dual-console setups. The installed base is over 1,700 systems and 15,000 surgeons trained on it already.

    ALEX: One thing that stood out to me in t

    This episode includes AI-generated content.
    続きを読む 一部表示
    7 分
  • UnitedHealth Q2 2026 Earnings Analysis

    UnitedHealth Q2 2026 Earnings Analysis
    2026/07/16
    More earnings analysis: https://betafinch.com
    Groups: HEALTHCARE (https://betafinch.com/groups/HEALTHCARE)
    ──────────
    **BETA FINCH — UnitedHealth Group (UNH) Q2 2026 Earnings Breakdown**

    ALEX: Welcome to Beta Finch, your AI-powered earnings breakdown. I'm Alex, joined as always by Jordan, and today we're digging into UnitedHealth Group's second quarter 2026 results — a quarter that, honestly, marks a pretty big turnaround story.

    JORDAN: Big turnaround is right. But before we get into it — quick reminder for everyone listening.

    ALEX: Right, this podcast is AI-generated content for educational and entertainment purposes only. Nothing we discuss should be considered investment advice. Always do your own research and consult a qualified financial advisor before making any investment decisions.

    JORDAN: Good, now let's get into it.

    ALEX: So let's start with the headline numbers, because they're strong. Adjusted EPS came in at $6.38, up from $4.08 a year ago — that's a huge jump. Revenue was about $112 billion, roughly flat year-over-year, but operating earnings grew 55%. And they raised full-year guidance to a range of $19.50 to $20 a share.

    JORDAN: What jumps out to me is the medical care ratio — that's basically the percentage of premium revenue that goes out the door in medical claims. It dropped to 86.7% from 89.4% last year. Lower is better for the insurer. Part of that is $860 million in favorable prior-period development, meaning they overestimated costs in prior periods and get to release some of that reserve now. But even stripping that out, the underlying trend is improving.

    ALEX: And this is really the story CEO Stephen Hemsley told at the top of the call — this is a company about a year into a restructuring after a rough stretch, and he was pretty clear: "we will remain restless." He's not declaring victory, but the discipline is showing up in the numbers.

    JORDAN: Let's talk segments, because the picture is genuinely split. Medicare Advantage was the star of the quarter. Membership retention beat expectations, they now expect MA enrollment to decline by only about 1.1 million instead of more, and Medicare margins are tracking above 3% for the year. Medical trend also came in below their original 10% estimate — helped by benefit redesign, network curation, and honestly, a milder flu season.

    ALEX: Meanwhile, commercial is the soft spot. Cost trends are running modestly above 11%, worse than they'd hoped. Management pointed to two specific culprits: the No Surprises Act's arbitration process — which they say is being exploited, with average payouts to out-of-network providers now 11 times what Medicare would pay — and more aggressive provider billing and coding practices.

    JORDAN: That arbitration point was one of the more eye-opening moments in the Q&A. Executive Dan Kueter said roughly 60% of all arbitration cases are now brought by just five entities, and 40% of claims entering the process are actually ineligible to begin with. It's clogging the system and driving costs up. The upshot: commercial margin recovery, which they'd hoped to complete by 2027, is now going to take longer. Not derailed, in their words — just delayed.

    ALEX: Medicaid, meanwhile, is basically playing out as planned — margins pressured, expected to land between -1% and -1.7% for the year, as state reimbursement rates lag behind medical cost growth. Nothing new there, just a slow grind toward better alignment with states.

    JORDAN: Now let's flip to Optum, the services side of the business, because that's where a lot of the AI story lives. Optum Health — their value-based care arm — is showing real improvement: a roughly 10% reduction in hospitalizations in regions where they've rolled out new care transition programs, and patient satisfaction up about 5% year-over-year.

    ALEX: Optum Rx, the pharmacy benefit manager, is leaning hard into transparency — they're on track to have more than 95% of clients on 100% rebate pass-through by year-end.

    This episode includes AI-generated content.
    続きを読む 一部表示
    7 分
  • Abbott Laboratories Q2 2026 Earnings Analysis

    Abbott Laboratories Q2 2026 Earnings Analysis
    2026/07/16
    More earnings analysis: https://betafinch.com
    Groups: HEALTHCARE (https://betafinch.com/groups/HEALTHCARE), INCOME (https://betafinch.com/groups/INCOME)
    ──────────
    Welcome to Beta Finch, your AI-powered earnings breakdown. Here's the Abbott Labs (ABT) Q2 2026 script.

    ---

    **ALEX:** Welcome to Beta Finch, your AI-powered earnings breakdown. I'm Alex, joined as always by Jordan, and today we're digging into Abbott Laboratories' second quarter 2026 results. Before we jump in, quick disclaimer — this podcast is AI-generated content for educational and entertainment purposes only. Nothing we discuss should be considered investment advice. Always do your own research and consult a qualified financial advisor before making any investment decisions.

    **JORDAN:** Thanks, Alex. And there's a lot to like in this print. Let's start with the headline numbers.

    **ALEX:** Right, so Abbott posted sales growth of 4.8% for the quarter — that's an acceleration from the last two quarters — and adjusted EPS of $1.31, which beat both the midpoint of their guidance and consensus estimates.

    **JORDAN:** And here's the part investors really zeroed in on — Abbott didn't just reaffirm full-year sales guidance of 6.5% to 7.5%, they actually raised their EPS guidance range to $5.45 to $5.60. CEO Robert Ford was pretty clear that gross margin expansion is doing a lot of the heavy lifting there — margins came in at 58%, up 100 basis points year-over-year.

    **ALEX:** Let's talk segments, because there's a real story of divergence here. Medical devices grew 8.5%, led by electrophysiology — that's the heart rhythm and ablation business — which grew in the low teens. EPD, their emerging markets pharma division, grew 9%, powered by India, Latin America, and Southeast Asia.

    **JORDAN:** Diagnostics was mixed. Core lab was strong, U.S. up 7.5%. But rapid and molecular diagnostics — that's respiratory testing — declined 8% because it was just a weak flu and respiratory virus season. That's expected and temporary though, not a demand problem.

    **ALEX:** And then nutrition — this is the comeback story of the quarter. Sales came in ahead of expectations for the second straight quarter, up sequentially by $125 million. Ensure retail consumption in the U.S. is up double digits.

    **JORDAN:** Yeah, that's the price increases from late last year finally working through the system — volumes are responding well now that consumers have adjusted. Management is now framing nutrition as a sustainable 2-4% grower going forward.

    **ALEX:** Let's get into the strategic stuff, because there's a lot of pipeline news. Abbott completed enrollment in its coronary IVL trial, filed with the FDA for the Amulet 360 left atrial appendage device, and got a CE mark in Europe for Libre Duo — which is notable, it's the world's first dual glucose-ketone monitoring sensor, designed to help prevent diabetic ketoacidosis.

    **JORDAN:** The CGM story is worth sitting with for a second. Diabetes care crossed $2 billion in quarterly sales, growing 9.5%. Now, one analyst on the call kind of poked at that number as "only" 9.5%, and Ford pushed back — reasonably, I'd say. He pointed out there's 75 to 80 million people globally who could realistically use a CGM, and only 15 million currently do. Growth right now is basically waiting on reimbursement expansion, especially the big one: U.S. Type 2 non-insulin Medicare coverage, which could unlock roughly 10 million beneficiaries. Ford said that could happen this fall but wouldn't pin down an exact date.

    **ALEX:** They're also planning a fifth manufacturing facility for CGM sensors — a billion-dollar investment — because they expect to hit capacity limits at their current facility within a couple years. That's a pretty strong signal of how bullish they are on long-term demand.

    **JORDAN:** One theme that came up repeatedly in the Q&A was this investor worry about decelerating hospital procedure volumes — tied to ACA enrollment changes and Medicaid dynamics.

    This episode includes AI-generated content.
    続きを読む 一部表示
    7 分